Highlights
- Revenue from operations stood at ₹820.00 lakh in Q1 FY27.
- Net profit came in at ₹61.24 lakh during the quarter.
- Board approved proposal to rename the company as Pasura Industries Limited, subject to shareholder approval.
- Company appointed Vivek Surana & Associates as Secretarial Auditor following the resignation of the previous auditor.
- Board also approved revisions in managerial remuneration and fixed the 40th AGM on August 12, 2026.
Arunjyoti Bio Ventures Q1 Results
Arunjyoti Bio Ventures Limited reported its unaudited financial results for the quarter ended 30 June 2026, showing lower year-on-year profitability despite returning to profit on a sequential basis. Alongside the financial results, the company announced several key corporate decisions, including a proposal to change its name to Pasura Industries Limited, subject to shareholder approval.
Financial Performance
Revenue from operations for the June 2026 quarter stood at ₹820.00 lakh, compared with ₹871.24 lakh in the corresponding quarter last year, reflecting a decline of around 5.9% YoY. Total income also decreased to ₹822.06 lakh from ₹872.45 lakh.
Total expenses increased to ₹740.22 lakh from ₹655.54 lakh in Q1 FY26, primarily due to higher employee benefit expenses and other operating costs. As a result, profit before tax declined sharply to ₹81.84 lakh from ₹216.91 lakh in the year-ago period.
After accounting for a total tax expense of ₹20.60 lakh, the company reported a net profit of ₹61.24 lakh, compared with ₹204.54 lakh in Q1 FY26, representing a 70.1% year-on-year decline. Earnings per share (EPS) also declined to ₹0.03 from ₹0.11 in the corresponding quarter last year.
On a sequential basis, however, the company returned to profitability after reporting a net loss of ₹540.09 lakh in the March 2026 quarter, which had been impacted by exceptional expenses.
Quarterly Performance
During the quarter ended 30 June 2026, Arunjyoti Bio Ventures reported revenue from operations of ₹820.00 lakh, compared with ₹871.24 lakh in the corresponding quarter of the previous year, reflecting a decline of around 5.9%. Profit before tax stood at ₹81.84 lakh, down from ₹216.91 lakh in Q1 FY26. After accounting for a tax expense of ₹20.60 lakh, the company reported a net profit of ₹61.24 lakh, compared with ₹204.54 lakh in the year-ago quarter, representing a 70.1% year-on-year decline. Earnings per share (EPS) also declined to ₹0.03 from ₹0.11 a year earlier. Despite the weaker year-on-year performance, the company returned to profitability on a sequential basis after reporting a net loss of ₹540.09 lakh in the March 2026 quarter, which had been affected by exceptional expenses.
Key Corporate Announcements
Apart from approving the quarterly financial results, the Board approved the proposal to change the company's name from Arunjyoti Bio Ventures Limited to Pasura Industries Limited, subject to shareholder approval.
The Board also accepted the resignation of Manoj Parakh & Associates as Secretarial Auditor and appointed Vivek Surana & Associates to fill the casual vacancy and serve as Secretarial Auditor for a period of five financial years (FY27 to FY31), subject to shareholder approval.
Additionally, the company approved revisions in remuneration for its Whole-time Directors, recommended waiver of recovery of excess managerial remuneration paid during FY26, approved the Directors' Report, and scheduled its 40th Annual General Meeting (AGM) for 12 August 2026 through video conferencing.
What Investors Will Look At
Investors are likely to focus on whether the company can restore revenue growth after reporting a decline in sales during the June quarter. Although profitability improved sequentially from the March quarter due to the absence of exceptional losses, earnings remained significantly below last year's level. Market participants will also monitor the execution of the company's proposed transition to Pasura Industries Limited, the impact of revised management compensation, and whether operational performance strengthens over the coming quarters.
Conclusion
Arunjyoti Bio Ventures began FY27 with lower revenue and significantly weaker profitability on a year-on-year basis, even though it returned to profit sequentially following the exceptional losses recorded in the previous quarter. Beyond the financial performance, the proposed corporate rebranding to Pasura Industries Limited and other governance-related decisions mark an important phase for the company. Going forward, investors will closely watch whether management can translate these strategic changes into sustained operational improvement and earnings growth.
FAQs
Q: What was Arunjyoti Bio Ventures' revenue in Q1 FY27?
A: The company reported revenue from operations of ₹820.00 lakh for the quarter ended 30 June 2026.
Q: How much net profit did Arunjyoti Bio Ventures report in Q1 FY27?
A: Arunjyoti Bio Ventures reported a net profit of ₹61.24 lakh, compared with ₹204.54 lakh in the corresponding quarter of the previous year.
Q: Why did Arunjyoti Bio Ventures' profit decline in Q1 FY27?
A: The decline in profit was primarily due to lower revenue and higher operating expenses compared with the year-ago quarter, resulting in lower profit before tax and net profit.
Q: What major corporate announcement did the company make along with its Q1 FY27 results?
A: The Board approved a proposal to change the company's name from Arunjyoti Bio Ventures Limited to Pasura Industries Limited, subject to shareholder approval.
Q: When is Arunjyoti Bio Ventures' 40th Annual General Meeting scheduled?
A: The company has scheduled its 40th Annual General Meeting (AGM) for 12 August 2026, which will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM).